Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CMRX
- CUSIP: N/A
- Web: www.chimerix.com
Capitalization:- Market Cap: $232.33 million
- Outstanding Shares: 46,651,000
Average Prices:- 50 Day Moving Avg: $5.20
- 200 Day Moving Avg: $5.45
- 52 Week Range: $3.66 - $6.64
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.75
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $5.55 million
- Price / Sales: 43.04
- Book Value: $5.65 per share
- Price / Book: 0.91
Profitability:- EBIDTA: ($68,500,000.00)
- Net Margins: -1,221.34%
- Return on Equity: -24.07%
- Return on Assets: -23.24%
Debt:- Current Ratio: 19.11%
- Quick Ratio: 19.11%
Misc:- Average Volume: 257,957 shs.
- Beta: 1.54
- Short Ratio: 8.19
Frequently Asked Questions for Chimerix (NASDAQ:CMRX)
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
How were Chimerix's earnings last quarter?
Chimerix, Inc. (NASDAQ:CMRX) issued its earnings results on Tuesday, May, 9th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.01. The business earned $1.08 million during the quarter, compared to analyst estimates of $1.56 million. Chimerix had a negative net margin of 1,221.34% and a negative return on equity of 24.07%. View Chimerix's Earnings History.
Where is Chimerix's stock going? Where will Chimerix's stock price be in 2017?
4 brokerages have issued 12 month price objectives for Chimerix's shares. Their predictions range from $6.00 to $12.00. On average, they anticipate Chimerix's stock price to reach $8.00 in the next year. View Analyst Ratings for Chimerix.
What are analysts saying about Chimerix stock?
Here are some recent quotes from research analysts about Chimerix stock:
- 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (7/17/2017)
- 2. FBR & Co analysts commented, "We attended Chimerix’s Investor/Analyst Day on April 27 in New York and came away looking forward to further clinical development in 2017 and 2018. Chimerix reported data from the single ascending dose (SAD) study with IV brincidofovir (BCV) and provided additional details on future clinical trials." (5/1/2017)
- 3. Cowen and Company analysts commented, "CMRX is developing brincidofovir as an inhibitor of several DNA viruses." (4/28/2017)
Who are some of Chimerix's key competitors?
Some companies that are related to Chimerix include Atara Biotherapeutics (ATRA), Progenics Pharmaceuticals (PGNX), Geron Corporation (GERN), Karyopharm Therapeutics (KPTI), Jounce Therapeutics (JNCE), G1 THERAPEUTICS (GTHX), BioCryst Pharmaceuticals (BCRX), Bellicum Pharmaceuticals (BLCM), Adaptimmune Therapeutics PLC (ADAP), GlycoMimetics (GLYC), BioSpecifics Technologies Corp (BSTC), Ra Pharmctl (RARX), Selecta Biosciences (SELB), Merus N.V. (MRUS), BioTime (BTX), Edge Therapeutics (EDGE), Corbus Pharmaceuticals Holdings (CRBP) and Rigel Pharmaceuticals (RIGL).
Who are Chimerix's key executives?
Chimerix's management team includes the folowing people:
- Ernest B. Mario Ph.D., Independent Chairman of the Board
- Michelle Berrey M.D., President, Chief Executive Officer, Chief Medical Officer, Director
- Timothy W. Trost CPA, Chief Financial Officer, Senior Vice President, Corporate Secretary
- Roy W. Ware Ph.D., Chief Manufacturing and Technology Officer
- Randall Lanier, Chief Science Officer
- W. Garrett Nichols M.D., Chief Medical Officer
- Linda M. Richardson, Chief Commercial Officer
- James M. Daly, Independent Director
- Martha J. Demski, Independent Director
- Catherine L. Gilliss Ph.D., Independent Director
Who owns Chimerix stock?
Chimerix's stock is owned by many different of institutional and retail investors. Top institutional investors include Prescott Group Capital Management L.L.C. (0.65%), US Bancorp DE (0.08%) and Moloney Securities Asset Management LLC (0.06%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, M Michelle Berrey and Martha J Demski. View Institutional Ownership Trends for Chimerix.
Who sold Chimerix stock? Who is selling Chimerix stock?
Chimerix's stock was sold by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC and US Bancorp DE. Company insiders that have sold Chimerix stock in the last year include Ernest Mario and John M Leonard. View Insider Buying and Selling for Chimerix.
How do I buy Chimerix stock?
Shares of Chimerix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chimerix's stock price today?
One share of Chimerix stock can currently be purchased for approximately $5.12.
MarketBeat Community Rating for Chimerix (NASDAQ CMRX)MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Chimerix (NASDAQ:CMRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.25) |
| Consensus Price Target: | $8.00 (56.25% upside) |
Analysts' Ratings History for Chimerix (NASDAQ:CMRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/1/2017 | FBR & Co | Reiterated Rating | Hold | $7.00 | High |  |
| 4/28/2017 | Cowen and Company | Reiterated Rating | Hold | $6.00 | Low | |
| 8/18/2016 | Piper Jaffray Companies | Set Price Target | Buy | $12.00 | N/A | |
| 8/9/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $7.00 | N/A | |
| 3/1/2016 | Citigroup Inc. | Reiterated Rating | Hold | | N/A | |
| 2/23/2016 | William Blair | Lower Price Target | Market Perform | $12.00 -> $8.00 | N/A | |
| 2/23/2016 | Barclays PLC | Downgrade | Overweight -> Equal Weight | $12.00 -> $6.00 | N/A | |
| 2/22/2016 | Morgan Stanley | Downgrade | Equal Weight -> Underweight | $8.00 -> $5.00 | N/A | |
| 1/3/2016 | Brean Capital | Downgrade | Hold | | N/A | |
| 1/3/2016 | Stifel Nicolaus | Downgrade | Hold | | N/A | |
| 12/30/2015 | Empire | Reiterated Rating | Equal Weight | | N/A | |
| 12/30/2015 | Janney Montgomery Scott | Lower Price Target | Neutral | $14.00 | N/A | |
| 9/8/2015 | Cantor Fitzgerald | Reiterated Rating | Buy | $57.00 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Chimerix (NASDAQ:CMRX)Earnings History by Quarter for Chimerix (NASDAQ CMRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($0.37) | ($0.38) | $1.56 million | $1.08 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($0.37) | ($0.32) | $0.89 million | $1.98 million | View | Listen | |
| 11/7/2016 | Q3 | ($0.39) | ($0.37) | $1.73 million | $0.65 million | View | Listen | |
| 8/8/2016 | Q2 | ($0.51) | ($0.39) | $1.98 million | $1.80 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.66) | ($0.57) | $2.79 million | $1.20 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.14) | ($0.82) | $8.07 million | $3.10 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.59) | ($0.70) | $5.01 million | $2.27 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.58) | ($0.59) | $1.37 million | $4.10 million | View | Listen | |
| 5/11/2015 | Q115 | ($0.59) | ($0.54) | $1.19 million | $1.20 million | View | Listen | |
| 3/6/2015 | Q414 | ($0.51) | ($0.52) | $1.13 million | $1.16 million | View | Listen | |
| 11/7/2014 | Q314 | ($0.41) | ($0.47) | $0.40 million | $1.19 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.46) | ($0.39) | $0.84 million | $0.92 million | View | N/A | |
| 5/9/2014 | Q1 14 | ($0.36) | ($0.39) | $0.85 million | $0.78 million | View | N/A | |
| 3/7/2014 | Q413 | ($0.41) | ($0.31) | $1.19 million | $0.88 million | View | N/A | |
| 11/14/2013 | Q3 | ($0.38) | ($0.26) | | | View | Listen | |
| 8/14/2013 | Q2 2013 | ($0.40) | ($0.91) | $1.91 million | $0.81 million | View | N/A | |
| 5/13/2013 | Q1 2013 | ($2.43) | ($22.58) | $1.00 million | $1.80 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Chimerix (NASDAQ:CMRX)2017 EPS Consensus Estimate: ($1.86)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.42) | ($0.34) | ($0.38) |
| Q2 2017 | 2 | ($0.45) | ($0.41) | ($0.43) |
| Q3 2017 | 2 | ($0.54) | ($0.44) | ($0.49) |
| Q4 2017 | 2 | ($0.62) | ($0.49) | ($0.56) |
(Data provided by Zacks Investment Research)
Dividend History for Chimerix (NASDAQ:CMRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Chimerix (NASDAQ:CMRX)Insider Ownership Percentage: 10.50%
Institutional Ownership Percentage: 66.72%
Insider Trades by Quarter for Chimerix (NASDAQ:CMRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/28/2016 | Ernest Mario | Director | Sell | 100,000 | $4.64 | $464,000.00 | |
| 9/15/2016 | John M Leonard | Director | Sell | 5,000 | $5.03 | $25,150.00 | |
| 8/29/2016 | M Michelle Berrey | Insider | Buy | 22,417 | $4.47 | $100,203.99 | |
| 6/24/2016 | Ernest Mario | Director | Buy | 50,000 | $3.70 | $185,000.00 | |
| 6/24/2016 | M Michelle Berrey | CEO | Buy | 13,188 | $3.69 | $48,663.72 | |
| 5/13/2016 | Ernest Mario | Director | Buy | 10,000 | $4.53 | $45,300.00 | |
| 5/11/2016 | Ernest Mario | Director | Buy | 25,000 | $4.85 | $121,250.00 | |
| 5/10/2016 | Ernest Mario | Director | Buy | 800 | $4.76 | $3,808.00 | |
| 3/16/2016 | Ernest Mario | Director | Buy | 25,000 | $5.06 | $126,500.00 | |
| 3/15/2016 | Ernest Mario | Director | Buy | 20,000 | $5.13 | $102,600.00 | |
| 3/1/2016 | Martha J Demski | Director | Buy | 10,000 | $4.89 | $48,900.00 | |
| 12/29/2015 | Ernest Mario | Director | Buy | 125,000 | $7.09 | $886,250.00 | |
| 11/2/2015 | Martha J. Demski | Director | Sell | 1,126 | $41.35 | $46,560.10 | |
| 10/1/2015 | Martha J. Demski | Director | Sell | 2,000 | $37.68 | $75,360.00 | |
| 9/1/2015 | Martha J. Demski | Director | Sell | 2,000 | $48.18 | $96,360.00 | |
| 8/21/2015 | John M Leonard | Director | Buy | 1,000 | $47.38 | $47,380.00 | |
| 7/17/2015 | Timothy W Trost | CFO | Sell | 28,000 | $50.00 | $1,400,000.00 | |
| 7/1/2015 | Martha J Demski | Director | Sell | 2,000 | $46.03 | $92,060.00 | |
| 6/1/2015 | Martha J Demski | Director | Sell | 2,000 | $41.58 | $83,160.00 | |
| 5/1/2015 | Martha J Demski | Director | Sell | 2,000 | $34.71 | $69,420.00 | |
| 3/2/2015 | Martha J Demski | Director | Sell | 2,000 | $40.18 | $80,360.00 | |
| 2/2/2015 | Martha J Demski | Director | Sell | 2,000 | $38.38 | $76,760.00 | |
| 1/2/2015 | Martha J Demski | Director | Sell | 2,000 | $41.08 | $82,160.00 | |
| 11/5/2014 | John M Leonard | Director | Buy | 4,000 | $29.00 | $116,000.00 | |
| 9/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $27.75 | $138,750.00 | |
| 9/11/2014 | James Niedel | Director | Sell | 1,099,949 | $29.39 | $32,327,501.11 | |
| 9/9/2014 | Sanderling Venture Partners V, | Major Shareholder | Sell | 122,950 | $29.28 | $3,599,976.00 | |
| 9/8/2014 | Timothy Wollaeger | Director | Sell | 100,000 | $24.54 | $2,454,000.00 | |
| 9/5/2014 | Ernest Mario | Director | Buy | 10,000 | $23.19 | $231,900.00 | |
| 8/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $25.13 | $125,650.00 | |
| 7/25/2014 | Timothy W Trost | Insider | Sell | 5,000 | $22.35 | $111,750.00 | |
| 6/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $22.74 | $113,700.00 | |
| 5/27/2014 | Ernest Mario | Director | Buy | 10,000 | $14.22 | $142,200.00 | |
| 5/27/2014 | M Michelle Berrey | Insider | Buy | 14,065 | $14.22 | $200,004.30 | |
| 5/27/2014 | Timothy W Trost | CFO | Sell | 5,000 | $17.41 | $87,050.00 | |
| 4/25/2014 | Timothy W Trost | Insider | Sell | 5,000 | $18.67 | $93,350.00 | |
| 3/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $25.37 | $126,850.00 | |
| 2/25/2014 | Timothy W Trost | CFO | Sell | 5,000 | $19.29 | $96,450.00 | |
| 1/27/2014 | Timothy W Trost | CFO | Sell | 5,000 | $18.26 | $91,300.00 | |
| 12/26/2013 | Timothy W Trost | CFO | Sell | 5,000 | $15.21 | $76,050.00 | |
| 12/13/2013 | Ernest Mario | Director | Buy | 5,000 | $13.90 | $69,500.00 | |
| 12/9/2013 | Rodman L Drake | Director | Buy | 1,000 | $14.35 | $14,350.00 | |
| 11/25/2013 | Ernest Mario | Director | Buy | 8,000 | $15.20 | $121,600.00 | |
| 11/19/2013 | Ernest Mario | Director | Buy | 7,500 | $15.25 | $114,375.00 | |
| 11/15/2013 | Rodman L Drake | Director | Buy | 1,000 | $15.56 | $15,560.00 | |
| 10/25/2013 | Timothy W Trost | CFO | Sell | 5,000 | $16.04 | $80,200.00 | |
| 10/23/2013 | Leaf Ventures Ii L.P. New | Major Shareholder | Sell | 585,602 | $15.51 | $9,082,687.02 | |
| 10/23/2013 | Vii L P Canaan | Director | Sell | 674,771 | $15.51 | $10,465,698.21 | |
| 8/30/2013 | Ernest Mario | Director | Buy | 5,064 | $15.82 | $80,112.48 | |
| 8/26/2013 | Ernest Mario | Director | Buy | 5,960 | $17.20 | $102,512.00 | |
| 8/23/2013 | M Michelle Berrey | Insider | Buy | 5,540 | $18.70 | $103,598.00 | |
| 8/20/2013 | Ernest Mario | Director | Buy | 4,040 | $17.48 | $70,619.20 | |
(Data available from 1/1/2013 forward)
Headline Trends for Chimerix (NASDAQ:CMRX)
Latest Headlines for Chimerix (NASDAQ:CMRX)
| Source: |
|
| Date | Headline |
|---|
 | Zacks Investment Research Upgrades Chimerix, Inc. (CMRX) to "Hold"
www.americanbankingnews.com - July 17 at 5:20 PM |
| Zacks: Brokerages Expect Chimerix, Inc. (CMRX) Will Announce Quarterly Sales of $1.23 Million
www.americanbankingnews.com - July 15 at 7:50 AM |
| Chimerix, Inc. (CMRX) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - July 13 at 8:28 PM |
| Chimerix, Inc. (CMRX) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 6:41 PM |
 | ETFs with exposure to Chimerix, Inc. : June 27, 2017
finance.yahoo.com - June 27 at 4:38 PM |
| Brokerages Anticipate Chimerix, Inc. (CMRX) Will Announce Quarterly Sales of $1.23 Million
www.americanbankingnews.com - June 21 at 9:08 AM |
| Chimerix Inc (CMRX) Expected to Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 19 at 8:44 PM |
| Edited Transcript of CMRX earnings conference call or presentation 9-May-17 12:30pm GMT
finance.yahoo.com - June 5 at 9:23 PM |
| ETFs with exposure to Chimerix, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 4:22 PM |
| Chimerix Inc (CMRX) Sees Large Decrease in Short Interest
www.americanbankingnews.com - June 3 at 5:28 PM |
| Chimerix, Inc. :CMRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 5:50 PM |
| $1.23 Million in Sales Expected for Chimerix Inc (CMRX) This Quarter
www.americanbankingnews.com - May 26 at 3:44 PM |
 | Chimerix: This Misunderstood Biotech, Trading Near Cash, Offers Substantial Upside - Seeking Alpha
seekingalpha.com - May 18 at 4:17 PM |
| Chimerix Inc (CMRX) to Post Q2 2017 Earnings of ($0.45) Per Share, William Blair Forecasts
www.americanbankingnews.com - May 12 at 10:40 AM |
| Q2 2017 Earnings Estimate for Chimerix Inc Issued By FBR & Co (CMRX)
www.americanbankingnews.com - May 11 at 9:09 AM |
| Chimerix Inc (CMRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 4:56 PM |
| Chimerix outlines plans for DNA virus drug
finance.yahoo.com - May 10 at 8:17 AM |
| Investor Network: Chimerix, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 4:23 PM |
| Chimerix Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 8:12 AM |
| Positive Media Coverage Very Likely to Impact Chimerix (CMRX) Share Price
www.americanbankingnews.com - May 3 at 8:54 PM |
| Brokerages Anticipate Chimerix Inc (CMRX) Will Post Quarterly Sales of $1.56 Million
www.americanbankingnews.com - May 3 at 2:35 PM |
| Chimerix to Announce First Quarter 2017 Financial Results on May 9, 2017
finance.yahoo.com - May 2 at 5:29 PM |
| Chimerix Inc (CMRX) Receives Hold Rating from FBR & Co
www.americanbankingnews.com - May 1 at 7:36 PM |
| Zacks: Brokerages Expect Chimerix Inc (CMRX) to Announce -$0.37 Earnings Per Share
www.americanbankingnews.com - May 1 at 5:46 PM |
| Somewhat Negative Media Coverage Likely to Impact Chimerix (CMRX) Stock Price
www.americanbankingnews.com - April 30 at 11:39 AM |
| Chimerix Inc (CMRX) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - April 29 at 1:02 AM |
| Chimerix (CMRX) Receives Media Sentiment Rating of 0.56
www.americanbankingnews.com - April 26 at 11:34 AM |
| ETFs with exposure to Chimerix, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 4:18 PM |
| Favorable News Coverage Somewhat Likely to Affect Chimerix (CMRX) Share Price
www.americanbankingnews.com - April 21 at 5:09 PM |
| Chimerix to Host Annual Investor Update on April 27, 2017
finance.yahoo.com - April 20 at 4:31 PM |
| Medical Device Stocks to Beat Estimates this Earnings Season
finance.yahoo.com - April 18 at 4:13 PM |
| Chimerix (CMRX) Earns Media Impact Rating of -0.08
www.americanbankingnews.com - April 16 at 11:51 AM |
| Zacks: Brokerages Expect Chimerix Inc (CMRX) Will Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - April 10 at 11:27 AM |
| ETFs with exposure to Chimerix, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 4:22 PM |
| CHIMERIX INC Financials
finance.yahoo.com - March 8 at 5:07 PM |
| Edited Transcript of CMRX earnings conference call or presentation 2-Mar-17 1:30pm GMT
finance.yahoo.com - March 2 at 9:38 PM |
| Chimerix reports 4Q loss
us.rd.yahoo.com - March 2 at 4:38 PM |
| CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 2 at 4:38 PM |
| Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 2 at 7:23 AM |
| Q4 2016 Chimerix Inc Earnings Release - Before Market Open
biz.yahoo.com - March 2 at 7:23 AM |
| Chimerix to Present at Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 1:03 PM |
| Chimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
finance.yahoo.com - February 23 at 4:21 PM |
| Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings
finance.yahoo.com - February 22 at 11:17 AM |
| 8:06 am Chimerix announces the presentation of final data from the AdVise trial of brincidofovir for the treatment of adenovirus infection in allogeneic hematopoietic cell transplant recipients at the BMT Tandem Meetings; results show highe
finance.yahoo.com - February 22 at 11:17 AM |
| Will Chimerix (CMRX) Continue to Surge Higher?
finance.yahoo.com - January 24 at 4:58 PM |
| CHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 4:49 PM |
 | Chimerix (CMRX) Names Randall Lanier as CSO; Roy Ware CMTO
www.streetinsider.com - January 5 at 9:56 PM |
 | 4:30 pm Chimerix appoints Randall Lanier, PhD, as Chief Science Officer
us.rd.yahoo.com - January 5 at 9:55 PM |
| Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer
finance.yahoo.com - January 5 at 4:54 PM |
| Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 5:24 PM |
Chimerix (CMRX) Chart for Thursday, July, 27, 2017
